secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001140361-23-045401
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis signs $60M upfront deal with Roche for two RNA programs for Alzheimer's and Huntington's
--------------------------------------------------------------------------------

- Ionis receives $60M upfront; Roche gains exclusive worldwide rights to develop and commercialize two undisclosed RNA-targeting medicines.
- Ionis responsible for pre-clinical advancement; Roche leads clinical development, manufacturing, and commercialization.
- Ionis eligible for development, regulatory, and commercial milestone payments plus tiered royalties.
- Programs target Alzheimer's disease and Huntington's disease; expands 10-year partnership including tominersen for HD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/0001140361-23-045401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/ef20011349_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-045401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer